United States· US:50090-7501_8e3ed594-772c-4762-abaf-eac7a114d9c7
Liraglutide
A liraglutide product containing liraglutide, registered in United States by A-S Medication Solutions. The same ATC class is registered in 16 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Liraglutide is registered in 16 of 19 countries.
Countries holding a registration under ATC A10BJ02 (liraglutide), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 10 of them publish a price we can compare per daily dose
Liraglutide · ATC A10BJ02
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- LIRAGLUTIDE
- Manufacturer
- A-S Medication Solutions
- Country
- United States (US)
- ATC code
- A10BJ02
- ATC class
- Liraglutide
- Defined daily dose
- 1.5 mg, P
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc1150090750103 SYRINGE, PLASTIC in 1 CARTON (50090-7501-0) / 3 mL in 1 SYRINGE, PLASTIC
- ndc1150090-7501-0
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
309 interactions on record for liraglutide.
Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Liraglutide · interactions on record
309 records
- 3 severe
- 260 moderate
- 46 minor
Most severe, free to view
- GatifloxacinJ01MA16severe
- SucralfateA02BX02moderate
- ThiethylperazinA04AB03moderate
- TriflupromazinA04AD06moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Liraglutide in 17 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaABLYMICOSTADA Arzneimittel AG, Bad Vilbel
- SpainBYESILOR 6 MG/ML SOLUCION INYECTABLE EN PLUMA PRECARGADA EFGSun Pharmaceutical Industries (Europe) B.V.
- SwedenAblymico 6 mg/ml Injektionsvätska, lösning i förfylld injektionspennaSTADA Arzneimittel AG
- United KingdomBiolide 6mg/ml solution for injection 3ml pre-filled pensBiocon Pharma UK Ltd
- NetherlandsAblymico 6 mg/ml oplossing voor injectie in een voorgevulde penStada Arzneimittel AG
- PolandAblymicoSTADA Arzneimittel AG
- GermanyByesilorBasics Gmbh
- FinlandAblymicoSTADA Arzneimittel AG
Authorised across Europe · EMA
The same active substance is authorised in 27 EEA countries. Names it is sold under:
- Austria · Ejulir, Lirabelin
- Belgium · Byesilor, Zinnentis
- Bulgaria · Зеглуксен
- Czechia · Ejulir, Plyzari
- Germany · Byesilor, Diavic
- Denmark · Ejulir, Liraglutid "biogaran"
- Estonia · Liraglutide Zentiva, Siluxir
- Spain · Byesilor, Diavic
- Finland · Diavic, Metlyra
- France · Liendax, Liraglutide Biogaran
- United Kingdom (Northern Ireland) · Diavic, Ligobesy
- Croatia · Zegluxen
- Hungary · Liendax
- Ireland · Ejulir
- Iceland · Ablymico, Liraglutide Stada
- Italy · Byesilor, Diavic
- Liechtenstein · Ablymico, Liraglutide Stada
- Lithuania · Liraglutide Zentiva
- Luxembourg · Zinnentis
- Latvia · Liraglutide Zentiva, Siluxir
- Netherlands · Byesilor, Diavic
- Norway · Ablymico, Liraglutid Zentiva
- Poland · Byesilor, Diavic
- Portugal · Liraglutido Farmoz, Liraglutido Pentafarma
- Romania · Byesilor, Diavic
- Sweden · Diavic, Ejulir
- Slovakia · Sudaclin
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ba74cc8c-5785-434a-86ca-c37b78cef257 GET /v1/drugs/ba74cc8c-5785-434a-86ca-c37b78cef257?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "SUBCUTANEOUS",
"source": "ndc",
"strength": "6",
"substance": "LIRAGLUTIDE",
"productndc": "50090-7501",
"dosage_form": "INJECTION",
"dea_schedule": null,
"strength_unit": "mg/mL",
"application_number": "NDA022341",
"marketing_category": "NDA AUTHORIZED GENERIC"
}See everything about liraglutide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.